Vimarsana
Biggest News Aggregation in the World

Page 3 - Mina Sooch News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mina Sooch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mina Sooch Today - Breaking & Trending Today

Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis - Vimarsana News

Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis - read this article along with other careers information, tips and advice on BioSpace

Ocuphire Pharma : Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update - Form 8-K - Vimarsana News

Ocuphire Pharma : Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update - Form 8-K

Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update Building Momentum with Completion of Patient... | March 24, 2022

Ocuphire Pharma to Present at Oppenheimer Annual Healthcare Conference - Vimarsana News

Ocuphire Pharma to Present at Oppenheimer Annual Healthcare Conference

10.03.2022 - FARMINGTON HILLS, Mich., March 10, 2022 (GLOBE NEWSWIRE) - Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal ...

Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day - Vimarsana News

Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day

New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia First update on recruitment in APX3330 ZETA-1 Phase 2b trial: ~70% patients... | January 31, 2022

Ocuphire Expands Prestigious Medical Advisory Board with - Vimarsana News

Ocuphire Expands Prestigious Medical Advisory Board with

FARMINGTON HILLS, Mich, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...